Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 507,769 shares of the medical research company's stock after acquiring an additional 29,351 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.09% of Edwards Lifesciences worth $37,590,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of EW. Abacus Planning Group Inc. grew its stake in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after buying an additional 140 shares during the period. Bowman & Co S.C. grew its stake in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock valued at $924,000 after buying an additional 148 shares in the last quarter. Pegasus Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock valued at $3,156,000 after purchasing an additional 159 shares in the last quarter. Mount Yale Investment Advisors LLC grew its stake in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock worth $634,000 after acquiring an additional 162 shares in the last quarter. Finally, Cooper Financial Group grew its position in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company's stock worth $479,000 after buying an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Finally, Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $79.95.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,303 shares of company stock valued at $3,255,356 over the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.07 during trading hours on Wednesday, reaching $68.46. The stock had a trading volume of 2,250,588 shares, compared to its average volume of 4,453,717. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $40.25 billion, a PE ratio of 9.82, a PEG ratio of 4.82 and a beta of 1.12. The stock's fifty day simple moving average is $72.03 and its 200 day simple moving average is $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.